Alltec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alltec

Quick Facts

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, Liquid, Chewable Tablet, Orally Disintegrating Tablet
Pharmacological class Antihistamine (Second-Generation H1 Antagonist)
Common use Symptomatic relief of allergic manifestations
Origin Synthetic (Piperazine derivative)

What Type of Medicine is Alltec (Cetirizine Hydrochloride)?

Alltec is a medicinal product defined by its active ingredient, Cetirizine Hydrochloride, which is classified as a second-generation antihistamine (H1-receptor antagonist). This pharmacological classification is clinically recognized for its high specificity in managing symptoms related to allergic conditions. This medicine is used to selectively block the chemical action responsible for typical allergy symptoms.

Composition and Forms of Alltec

Cetirizine Hydrochloride is a synthetic compound derived from the chemical structure of hydroxyzine. As a single-component product, its final composition includes the active ingredient alongside necessary pharmaceutical excipients. Alltec is designed for oral administration and is available in multiple dosage forms, including the standard tablet, syrup (liquid), and chewable tablet. The availability of liquid and chewable preparations makes this formulation particularly suitable for pediatric patient groups, providing an alternative to traditional tablets.

Core Purpose: How Does the Second-Generation Classification Benefit the Patient?

The essential function of Alltec is to counteract the immediate effects of histamine by selectively inhibiting peripheral H1 receptors. The primary benefit of the drug’s designation as a second-generation agent lies in its limited ability to cross the blood-brain barrier. This key characteristic, characterized by pharmacological properties, ensures the medicine provides effective symptomatic relief while substantially decreasing the likelihood of inducing pronounced sedation, which is a differentiating factor from older antihistamine agents.

Regulatory References

  1. Cetirizine: LiverTox (NIH)
  2. Cetirizine: MedlinePlus Drug Information (NIH)

What side effects are possible with Alltec?

Possible Side Effects and Safety Information

The safety profile of Cetirizine Hydrochloride (Alltec) is formally organized in regulatory documents, classifying potential adverse reactions by both frequency and the System-Organ Class (SOC) affected.


Officially Documented Adverse Reactions

The most Common adverse reactions documented in regulatory labeling include somnolence (drowsiness), fatigue, headache, and dry mouth. The official categorization places side effects into standard regulatory frequency groups:

Frequency Classification Examples of Documented Adverse Reactions
Common (≥1/100 to <1/10) Somnolence, Fatigue, Headache, Dizziness, Dry mouth
Uncommon (≥1/1,000 to <1/100) Agitation, Paresthesia, Diarrhea, Pruritus, Rash
Rare (<1/1,000) Hypersensitivity, Tachycardia, Hepatic function abnormal, Weight increased
Very Rare (<1/10,000) Anaphylactic shock, Thrombocytopenia, Blurred vision, Oculogyric crisis

Serious adverse reactions are primarily confined to the Rare or Very Rare categories, notably including anaphylactic shock and clinically significant abnormalities in hepatic function.


Safety Restrictions and Special Considerations

The medicine is formally contraindicated in individuals with a known history of hypersensitivity to the active substance, its excipients, or related compounds like hydroxyzine or any piperazine derivatives. Official documents advise caution regarding the potential for impaired alertness due to CNS effects, particularly when used concurrently with alcohol or other CNS depressants.

Specific constraints apply to certain populations: dose adjustment is required for patients with renal impairment, and the medicine is strictly contraindicated in those with end-stage renal disease (eGFR <15 mL/min). Furthermore, post-marketing reports document instances of severe, generalized pruritus (itching) following the cessation of prolonged, daily administration.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Overexposure to Alltec is documented in regulatory sources to affect the central nervous and cardiovascular systems. Manifestations commonly reported in overdose include somnolence (excessive drowsiness), sedation, dizziness, and headache. High-dose exposure is associated with a severe spectrum of CNS effects, including agitation, confusion, hallucinations, and potentially life-threatening events such as seizures and coma. Systemic signs that are also officially described include tachycardia (fast heart rate), hypotension (low blood pressure), fever, and urinary retention.

When to Seek Urgent Medical Attention

The official regulatory guidance mandates that individuals get medical help or contact a Poison Control Center right away in all cases of suspected overexposure. Immediate emergency services (911) must be contacted if the affected person displays severe symptoms, such as having a seizure, experiencing trouble breathing, or suffering a loss of consciousness or inability to be awakened. Overdoses may result in more severe symptoms, particularly in children and older adults, with children sometimes exhibiting initial excitement.

Official Management Profile

The official profile states that no known specific antidote to cetirizine exists. Treatment is therefore required to be symptomatic and supportive. Due to the risk of cardiovascular complications like arrhythmia, hospital monitoring and assessment via ECG (Electrocardiogram) may be necessary in cases of significant overexposure, as outlined in regulatory management guidelines.

Therapeutic Uses of Alltec

Therapeutic Indications and Mechanism

Alltec contains cetirizine hydrochloride, a second-generation antihistamine used to manage symptoms associated with allergic reactions. It functions by selectively antagonizing peripheral H1 receptors, which prevents histamine—a chemical released by the immune system during an allergic response—from binding to its receptors and causing common allergy symptoms.

Seasonal and Perennial Allergic Rhinitis

Alltec is primarily used to relieve symptoms triggered by airborne allergens such as pollen (hay fever), dust mites, animal dander, and molds. These symptoms typically include:

  • Nasal congestion and sneezing: Reducing the inflammation of the nasal passages.
  • Rhinorrhea: Decreasing the production of excess nasal mucus (runny nose).
  • Ocular symptoms: Relieving redness, itching, and excessive tearing of the eyes (allergic conjunctivitis).
  • Itching: Alleviating the persistent itching of the nose and throat.

Chronic Idiopathic Urticaria

Beyond respiratory allergies, Alltec is used in the treatment of chronic idiopathic urticaria. This condition is characterized by the sudden appearance of wheals (hives) and localized swelling of the skin (angioedema) without a clearly identifiable external cause. The medication helps to:

  • Reduce the number and size of hives.
  • Significantly diminish the associated itching and skin discomfort.

Benefits of Second-Generation Antihistamines

As a second-generation antihistamine, cetirizine offers specific therapeutic advantages in the management of allergies:

  • Duration of Action: The molecular structure allows for prolonged receptor binding, which typically provides relief for up to 24 hours with a single application.
  • Selectivity: It primarily targets peripheral receptors rather than those in the central nervous system. This reduces the likelihood of significant sedation compared to first-generation antihistamines, although individual sensitivity may vary.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Alltec (Cetirizine Hydrochloride) eligibility is strictly defined by government regulatory documents, focusing on absolute contraindications and conditional use.

Populations Who Must Not Use Alltec

Use of Alltec is contraindicated for patients with known hypersensitivity to the active ingredient, any excipients, hydroxyzine, or any piperazine derivatives.

It is also formally contraindicated for individuals with severe renal impairment, typically defined as a Creatinine Clearance less than 10 mL/min.

Age and Conditional Use

Population Regulatory Status
Children < 6 years (Tablets) Not recommended (does not allow dose adjustment). Liquid forms may be approved ge 6 months (by region).
Lactating Women Not recommended or Contraindicated (excretion in breast milk).
Pregnancy Conditional use; only after medical consultation and if clearly needed.
Moderate Renal Impairment Restricted use; dose reduction is required.
Urinary Retention Risk/Epilepsy Conditional use; caution and medical guidance are required.

Adults and adolescents ge 12 years with normal organ function are eligible for standard labeled use. Eligibility for all other groups is dependent on the constraints documented by regulatory authorities.

What should I know about interactions with other medicines?

The official regulatory documentation for Alltec (Cetirizine Hydrochloride) defines its interaction profile based on specific pharmacokinetic and pharmacodynamic patterns. No mandatory timing separation rules are documented for co-administration, and no specific drug-drug combination is formally classified as contraindicated solely due to interaction risk.

Documented Interaction Patterns

Interaction Type Interacting Substance Official Regulatory Outcome
Pharmacodynamic Alcohol, CNS Depressants May cause additive CNS impairment or additional reduction in alertness.
Pharmacokinetic Theophylline (400 mg dose) Causes a 16% decrease in cetirizine clearance, which increases systemic exposure.
Drug-Food Food Slows the rate of absorption ( C max reduced, T max delayed) but does not affect the total extent of absorption (AUC).

Regulatory studies found no clinically significant pharmacokinetic interactions when Alltec was co-administered with Azithromycin, Erythromycin, Ketoconazole, or Pseudoephedrine. The medicine is not substantially metabolized by the CYP450 enzyme system.

Population-Specific Clearance Note

Official labeling includes specific cautions regarding drug clearance in certain populations. Cetirizine clearance is officially stated to be reduced in patients with renal impairment and similarly reduced in patients with hepatic impairment. This acknowledgment of reduced drug clearance in organ impairment is integral to the product's defined regulatory profile.

Mechanism of Action

Pharmacodynamic Mechanism of Action

Alltec's mechanism is defined by the selective antagonism of the peripheral Histamine H1-receptor (H1-R). The molecule binds competitively to the H1-R, primarily located on endothelial cells and smooth muscle, initiating a rapid interruption of the associated Gq/ 11 protein signaling cascade. This molecular action directly intercepts the initial biochemical trigger for the histamine-driven physiological cascade.

By blocking the H1-R, the drug engages mechanisms that modulate overactive physiological responses related to tissue integrity. This action limits the histamine-mediated increase in vascular permeability and contributes to the maintenance of the integrity of the endothelial lining. The resulting physiological effect is a reduction in fluid leakage and localized tissue swelling, which results in a modulated activity level within targeted peripheral pathways.

The drug's structure ensures its action is predominantly peripheral, as its limited ability to cross the Blood-Brain Barrier (BBB) minimizes central H1-receptor occupancy, restricting its mechanistic influence to peripheral pathways.

Dosage and Administration Information

Instruction Map: How to use Alltec — Administration Guidelines

Alltec (Cetirizine Hydrochloride) administration follows standard parameters, outlining the route, dosing, frequency, and necessary adjustments for use.

Administration Scope

Feature Guideline
Route of administration Oral for routine systemic relief; Intravenous (IV) Injection for acute clinical use.
Dosing schedule Adults (≥ 12 years): Standard dose is 10 mg once daily, representing the maximum daily dose. A 5 mg dose may be used for less severe symptoms.
Timing in relation to meals May be taken with or without food; food intake does not alter the total systemic exposure.
Age-group administration rules Older Adults (≥ 65 years): Initiation at the lower 5 mg daily dose is utilized, particularly if renal function is reduced. Pediatric (6–11 years): Doses range from 5 mg to 10 mg daily.
Special procedural conditions Renal Impairment: Dose reduction is required; for example, moderate impairment necessitates 5 mg once daily. The IV solution is administered as a slow push in a clinical setting.

Instruction Classifications (High-Level)

Classification Principle
Administration method type Oral and Intravenous (Systemic).
Frequency pattern Once-daily (Every 24 hours) for standard regimens.
Use-context constraints Dosing is constrained by patient renal status and an absolute 10 mg daily maximum.

Connection to the overall use protocol

The administration protocol establishes a framework centered on once-daily administration and a 10 mg maximum dose for adults. This structure defines the route, frequency, and dosage limits within which the medicine is used. It also includes specific dose modifications for populations with known physiological differences, such as reduced renal function, ensuring use adheres to established parameters.

Recent Clinical Evidence

Research Evidence for Alltec (Cetirizine Hydrochloride)

The evidence base includes Randomized Controlled Trials (RCTs) and subsequent systematic reviews that combine findings from multiple studies. This research examined outcomes related to physical discomfort and functional imbalance in the context of allergic conditions. The studies focused on understanding symptom patterns and how outcomes related to daily functioning were measured in the observed populations.


Research Evidence for Symptom Management of Seasonal and Perennial Allergies

Research has explored the evaluation of Seasonal Allergic Rhinitis (hay fever) symptoms and their change over time. Studies relevant in trials assessing short-term or episodic symptom patterns examined how patient-reported outcomes describing perceived discomfort evolved over short time frames. For Perennial Allergic Rhinitis (year-round allergies), studies were applied in research contexts involving fluctuating or unstable symptoms over intermediate-term observation intervals, often extending up to 12 weeks.


Evidence Landscape for Managing Acute and Chronic Hives (Urticaria)

Alltec was evaluated in studies exploring chronic skin conditions that may vary in intensity, specifically Chronic Idiopathic Urticaria (CIU). Research examined key outcomes related to physical discomfort, such as the severity of itching (pruritus) and the appearance of weals (hives). For Acute Urticaria, very short-term trials monitored outcomes describing episodic or acute changes. The evidence available for the oral form's isolated effect on eye symptoms appears to be less extensive than the evidence for its other evaluated indications.


Evidence Gaps and Areas of Scientific Uncertainty

Research has explored the use of Alltec across different age groups, including adolescents and children. However, results apply only to the populations studied, and data for certain young groups remain insufficient compared to the extensive research in adults. Long-term effects are not fully established, as most well-controlled studies focused on short- or intermediate-term symptom change. Data for certain specific subgroups remains insufficient. The evidence highlights what is known—and what is still uncertain—about group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
  2. Cetirizine: Package Insert / Prescribing Information (FDA Monograph/DailyMed)
  3. Clinical Practice Guidelines: Urticaria (The Royal Children's Hospital, informed by major guidelines)

Frequently Asked Questions (FAQ)

Common questions about Alltec (FAQ)


Q: How quickly can I expect Alltec to start working?

A: According to the official product information from clinical trials, the antihistaminic activity following a single dose began within 20 minutes in 50% of the tested subjects. Furthermore, 95% of subjects experienced activity within one hour. This data indicates a rapid onset of the drug's intended action.

Q: Is it normal to feel [vague side effect, e.g., tired] when starting Alltec?

A: Regulatory documents classify somnolence (drowsiness) and fatigue (tiredness) as Common adverse reactions. This means these effects were observed in at least 1 out of every 100 people and up to 1 out of every 10 people in clinical trials, reflecting that they are among the most frequently reported effects.

Q: Do studies show that Alltec's effects are long-lasting?

A: Regulatory documents state that the antihistaminic activity following a single 10 mg dose persisted for at least 24 hours in clinical studies. This duration is consistent with the drug's established once-daily administration schedule.

Q: How long after stopping Alltec does it take for the drug to leave my system?

A: The mean elimination half-life for the active ingredient in Alltec is approximately 8 hours in adults with normal organ function. Pharmacokinetic principles indicate that the active ingredient's presence decreases significantly over a period of time based on its half-life.

Q: Is it possible to have no side effects while taking Alltec?

A: Clinical trial data show that side effects classified as Common occur in only a minority of users (less than 10% for most effects). Therefore, based on the clinical evidence, many patients in the studies did not report the most frequently listed adverse reactions.

Q: Does Alltec interact with common over-the-counter pain relievers?

A: Official data found no significant pharmacokinetic interactions when the active ingredient in Alltec was used alongside common pain-relief ingredients such as ibuprofen or acetaminophen. Regulatory warnings mention that using this drug with cold and flu products containing other sedating antihistamines may increase drowsiness.

Q: Are there any specific foods or drinks I should avoid while taking Alltec?

A: Official documentation states that the use of alcohol should be avoided or limited while taking Alltec. This is because the combination may cause an increase in nervous system side effects such as drowsiness. No other specific food or drink is listed as requiring avoidance.

Q: Do I need to change my diet while on Alltec?

A: Official documents on drug-food interactions indicate that taking Alltec with food only slows the rate at which the drug is absorbed, but it does not change the total amount of the drug that enters the body. There is no regulatory advice to make general changes to your diet while using this medication.

Q: Does Alltec interact with common dietary supplements like vitamins?

A: Official safety guidance notes that combining Alltec with herbal remedies or dietary supplements that are known to cause sedation, dry mouth, or difficulty with urination could result in an additive increase in these effects.

Q: Can Alltec cause long-term side effects?

A: Post-marketing reports document cases of new onset pruritus (severe itching) following the cessation of prolonged, daily administration of Alltec. As most well-controlled studies focused on short- or intermediate-term symptom changes, long-term effects beyond those reports are not fully established.

Q: What is the maximum amount of time someone can take Alltec?

A: Official studies and guidelines support the continuous use of Alltec for chronic conditions when needed. No maximum duration is formally specified in the regulatory labeling, but long-term use may be associated with the development of pruritus if treatment is abruptly stopped.

Q: Does Alltec cause weight changes?

A: In the official adverse reaction data from clinical trials, an increase in weight is documented as a Rare side effect, occurring in fewer than 1 out of 1,000 people. There are no data documenting a risk of weight loss.

Q: Are there any genetic factors that affect how Alltec works?

A: Official pharmacokinetic data indicates that the active ingredient is not substantially metabolized by the cytochrome P450 enzyme system. This system is a major pathway responsible for processing many medications and can be a source of genetic variability in drug response.

Q: What is the risk of overdose with Alltec?

A: Symptoms of overdose documented in regulatory reports include fever, fast heart rate, and confusion, which may progress to coma or urinary retention. Regulatory documents state that suspected overdose requires prompt medical evaluation.

Q: What kind of monitoring is recommended while taking Alltec?

A: Official labeling recommends monitoring for typical antihistaminic side effects during acute intravenous administration in a clinical setting. Close monitoring may also be advised by a healthcare provider when Alltec is co-administered with certain other medications, such as those that are P-glycoprotein substrates.

Q: Can I crush or split Alltec tablets?

A: The official administration instruction for the chewable tablet form is to chew or crush the tablet completely before swallowing. For other specific oral formulations, such as the standard tablet or orally disintegrating tablet, patients must follow the distinct instructions provided on the specific product packaging.

How should Alltec be stored and disposed of?

Storage and Disposal Requirements

Alltec (cetirizine hydrochloride) must be stored strictly according to the conditions defined in official regulatory labeling to ensure product integrity.

Storage Conditions

Requirement Specific Condition
Required Temperature Store at Controlled Room Temperature: 20C to 25C (68F to 77F).
Environmental Protection Protect from light and avoid high humidity. Avoid excessive heat above 40C (104F).
Container Integrity Do not use the product if the packaging seal (inner foil or safety seal) is broken or missing.

Safety and Disposal

The medicine must be kept out of reach of children at all times. Disposal of any unused or expired product must be done in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alltec found in:

A-Z Index: